Does holding at 60 mg for two weeks before escalating reduce early satiety?

What I am working with: 60 mg · two weeks · early satiety.

I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious.

My background is quantitative but not chemical, so I can follow an equation more easily than a hand-wave.

What is the causal chain, and where does it stop being established?

Put another way, what the label says and what the trial protocols permitted are different documents, and the difference is instructive: protocols generally allowed a step to be delayed or reversed for intolerance, and a substantial minority of participants used that provision.

The maintenance question turns on what you are maintaining. If the objective is weight maintenance, the withdrawal-extension data suggests that a fraction of the therapeutic dose retains a substantial fraction of the effect. If the objective is the cardiovascular or renal endpoint, the trials that demonstrated those endpoints used the full dose, and extrapolating downward is not supported by anything.

The argument against splitting a weekly dose is arithmetic rather than ideological. Peak-to-trough ratio for a seven-day half-life compound dosed weekly is about two. Split it into twice-weekly and the ratio falls to roughly 1.4. That is a real reduction in fluctuation and a negligible one in absolute terms, and you have doubled the number of stopper piercings and the number of small-volume measurements, each of which carries its own error.

SURMOUNT-4 is the withdrawal trial to read on the maintenance question: after an open-label lead-in, randomised withdrawal produced substantial regain in the placebo arm while continued treatment produced continued loss. It is the cleanest available answer to "what happens if I stop".

Write down in advance what would make you hold a step, because deciding that in the middle of a bad week is not when you are at your most analytical.

More usefully, answering this requires distinguishing the maximum studied dose from the maximum useful dose. The trials established the former. The latter is a per-person question that the trials were not designed to answer.

Steady state, worked: with a half-life of about seven days and weekly administration, the accumulation ratio is roughly 1/(1 − 0.5) = 2, and you get to within about 97 per cent of steady state after five half-lives, so around thirty-five days — five weeks — after any dose change. A four-week step interval therefore has you escalating at roughly 94 per cent of the previous dose’s steady state, which is close enough to be sensible and not so close as to be conservative.

Where the label ladders differ between agents, the differences track the potency ratio and the tolerability profile rather than anything deeper. It is worth reading the ladders side by side once, because the pattern — small starting dose, four-week steps, a defined maintenance range and a defined maximum — is identical in structure across the class.

The caveat that matters: dose decisions on a licensed medicine belong with a prescriber, and dose decisions on research-use-only material belong to a category where nobody has any obligation to you at all.

The short version: four-week steps because that is steady state, and the ladder is about the side effects, not the result.

For a compound with a seven-day half-life, dose timing is much less consequential than people expect and dose rate is much more consequential.

Holding at a step for longer than four weeks before escalating does appear to reduce cumulative gastrointestinal burden, which is unsurprising given that adverse events cluster in the one to two weeks after each increase. What it does not do is change where you end up, provided you get there.

The pharmacokinetics of the acylated agonists are well described: absorption from the subcutaneous depot is slow and rate-limiting, the elimination half-life is approximately one week, and steady state is reached in four to five weeks. Every dosing question in this section follows from those three facts.

The limitation of all trial-derived dosing reasoning is that trial populations were selected, monitored and supported in ways that do not resemble anyone reading this.

Escalate on tolerability, hold when it costs you, and do not confuse a flattening curve with a failing drug.

The steady-state arithmetic is worth doing once, because it explains most of what people find confusing about weekly dosing.

Escalating in response to a plateau is a specific and common error of reasoning. A plateau after four to six months is the expected trajectory in every trial in the class — the curve flattens because energy expenditure falls with mass, not because the receptor stopped working. A dose step may still be reasonable; "the loss stopped" is not by itself the reason.

The STEP programme escalated semaglutide over sixteen weeks in four-week steps to 2.4 mg weekly, and the trial-product estimand versus treatment-policy estimand distinction accounts for most of the difference between the figures quoted from those papers.

Read the actual prescribing information for the agent in question. It is short, specific, and more reliable than any summary of it.

edited 21 Sept 2024 by nine_point_nine — clarified the distinction between purity and content